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Abstract
Context:  Cardiac  surgery  patients  undergoing  coronary  artery  bypass  grafting  with  cardiopul-
monary bypass.
Objective:  Evaluate  the  effect  of  adding  intrathecal  sufentanil  to  general  anesthesia  on  hemo-
dynamics.
Design: Prospective,  randomized,  not  blinded  study,  after  approval  by  local  ethics  in  Research
Committee.
Setting: Monocentric  study  performed  at  Dante  Pazzanese  Institute  of  Cardiology,  Sao  Paulo,
Brazil.
Patients:  40  consenting  patients  undergoing  elective  coronary  artery  bypass,  both  genders.
Exclusion  criteria:  Chronic  kidney  disease;  emergency  procedures;  reoperations;  contraindica-
tion to  spinal  block;  left  ventricular  ejection  fraction  less  than  40%;  body  mass  index  above
32  kg/m2 and  use  of  nitroglycerin.
Interventions:  Patients  were  randomly  assigned  to  receive  intrathecal  sufentanil  1  g/kg  or  not.
Anesthesia induced  and  maintained  with  sevoﬂurane  and  continuous  infusion  of  remifentanil.
Main  outcome  measures:  Hemodynamic  variables,  blood  levels  of  cardiac  troponin  I,  B-type
natriuretic peptide,  interleukin-6  and  tumor  necrosis  factor  alfa  during  and  after  surgery.
Results:  Patients  in  sufentanil  group  required  less  inotropic  support  with  dopamine  when  com-
pared  to  control  group  (9.5%  vs  58%,  p  =  0.001)  and  less  increases  in  remifentanil  doses  (62%
vs  100%,  p  =  0.004).  Hemodynamic  data  at  eight  different  time  points  and  biochemical  data
showed  no  differences  between  groups.
Conclusions:  Patients  receiving  intrathecal  sufentanil  have  more  hemodynamical  stability,  as
suggested  by  the  reduced  inotropic  support  and  fewer  adjustments  in  intravenous  opioid  doses.
©  2013  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  
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ntroduction
ntrathecal  opioids  in  combination  with  general  anesthesia
educe pain  intensity  and  anesthetics  consumption  facilitat-
ng early  removal  of  the  endotracheal  tube  and  improving
ostoperative analgesia  in  patients  undergoing  coronary
rtery bypass  grafting  (CABG)  with  cardiopulmonary  bypass
CPB). Furthermore,  they  can  decrease  surgical  stress
esponse and  have  cardioprotective  effects.1--5 In  CABG
urgery, prevention  of  perioperative  adverse  events,  such
s tachycardia  and  myocardial  infarction,  is  advisable.
emodynamic stability  and  reduction  of  stress  response  con-
ribute, in  part,  to  reduce  myocardial  damage.1,6
Compared  to  morphine,  intrathecal  sufentanil  provides
aster and  more  intense  analgesia.3,7 In  fact,  because  of
orphine’s lipid  solubility,  analgesic  effects  after  intrathe-
al injection  are  delayed  and  only  large  intrathecal  doses
10 mg)  may  initiate  reliable  intraoperative  analgesia  in  this
etting.3 Besides  that,  some  authors  suggest  that  intrathe-
al sufentanil  provides  better  hemodynamic  stability  when
ompared to  other  opiods.2,8
The  aim  of  this  study  was  to  evaluate,  for  the  ﬁrst  time,
he hemodynamic  effects  of  adding  intrathecal  sufentanil  to
eneral anesthesia  in  patients  undergoing  coronary  artery
ypass grafting  with  cardiopulmonary  bypass.
ethods
thical  approval  for  this  study  (protocol  number  CEP  3458)
as provided  by  the  Ethical  Committee  CEP  Istituto  Dante
azzanese of  São  Paulo,  Brasil  on  29  August  2006.  After  writ-
en informed  consent  we  enrolled  40  patients  scheduled  to
ndergo elective  CABG  with  CPB  with  two  to  four  grafts,  with
ne graft  always  being  the  left  internal  mammary  artery  and
he others  the  safena  magna  vein.
Exclusion  criteria  were:  chronic  kidney  disease;  emer-
ency procedures;  reoperations;  contraindication  to  spinal
lock according  to  2002  American  Society  of  Regional  Anes-
hesia Consensus  Conference9;  left  ventricular  ejection
raction less  than  40%;  body  mass  index  (BMI)  above  32  kg/m2
nd  use  of  nitroglycerin.
Patients  were  randomly  assigned  to  two  different
nesthetic protocols  (sufentanil  group  or  control  group)
epending on  receiving  or  not  intrathecal  sufentanil.  A  com-
uter  generated  random  table  determined  in  which  group
atients were  allocated.  The  participants’  randomization
ssignment was  concealed  in  an  envelope  until  the  last  avail-
ble moment  (start  of  anesthesia).
Patients  received  their  usual  medications  until  the  day  of
peration, with  the  exception  of  oral  hypoglycemic  agents,
hich were  discontinued  and/or  replaced  by  insulin  at  least
hree days  before  surgery.  All  patients  received  7.5  mg  of
idazolam intramuscularly  1  h  before  surgery.
Monitoring included  continuous  electrocardiography  of
he DII  and  modiﬁed  V5,  analysis  of  the  ST  segment  in  DII,
I and  modiﬁed  V5  derivations,  pulse  oximetry,  invasive
ean blood  pressure  (MAP)  positioned  in  the  radial  artery,
nalysis of  the  bispectral  index  (BIS),  capnography,  blood
as analysis,  temperature  measurement  at  the  lower  third
f the  esophagus,  urinary  catheterization,  assessment  of
euromuscular function  with  TOF  WATCH  and  evaluation  of
o
w
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emodynamic  data  made  with  a pulmonary  artery  catheter
Swan-Ganz model,  continuous  output),  positioned  on  the
ight subclavian  vein  (monitor  Vigilance  II®,  Edwards  Life-
ciences, Irvine,  CA,  USA).
In  sufentanil  group,  after  initial  monitoring,  patients
ere placed  in  a  sitting  position  and  underwent  lumbar
uncture in  the  L3--L4  space  with  a  25  gauge  Whitacre  nee-
le. After  conﬁrmation  of  puncture  of  the  subarachnoid
pace, successful  spinal  was  given  to  all  these  patients,  5  mL
f saline  solution  0.9%  containing  1  g/kg  sufentanil  (and
ever more  than  100  g)  was  injected  over  a  10  s period.
eneral anesthesia  was  then  initiated.
In  control  group,  general  anesthesia  was  initiated  imme-
iately after  initial  monitoring.
All  patients  underwent  inhalation  induction  as  follows:
acial mask  with  using  2%  sevoﬂurane  in  100%  oxygen  and
resh gas  ﬂow  of  6  L/min  for  30  s.  Inspired  concentra-
ion of  sevoﬂurane  was  then  increased  to  7%  until  loss  of
onsciousness and  then  reduced  to  2%.  Next,  intravenous
nfusion of  remifentanil  began  at  a  dose  of  1 g/kg  for
 min  and  0.1  mg/kg  pancuronium  was  administered  3  min
efore tracheal  intubation.  Volume-controlled  ventilation
as started  with  the  following  parameters:  tidal  volume
--10 mL/kg,  respiratory  rate  adequate  to  maintain  end  Tidal
O2 between  30  and  35  mmHg  and  fresh  gas  ﬂow  of  2  L
ith 60%  fraction  of  inspired  oxygen  mixed  with  compressed
ir.
The maintenance  of  anesthesia  in  the  period  before  and
fter CPB  was  performed  with  sevoﬂurane  in  the  expired
raction with  variation  between  0.5%  and  2%  to  maintain
he BIS  between  40  and  65.  Remifentanil  was  administered
t an  infusion  rate  up  to  0.4  g/kg/min  to  maintain  mean
rterial pressure  levels  between  60  and  80  mmHg.  A  bolus
f 0.02  mg/kg  pancuronium  was  administered  when  the  third
esponse to  the  sequence  of  four  stimuli  appeared  in  the  TOF
ATCH monitor  until  the  end  of  the  procedure.
During  CPB,  anesthesia  was  maintained  with  sevoﬂurane
t levels  between  0.5%  and  2%  administered  together  with  a
ixture of  oxygen  and  compressed  air  in  the  oxygenator  cir-
uit through  calibrated  vaporizer  to  maintain  the  BIS  value
etween 40  and  65  and  remifentanil  up  to  0.4  g/kg/min  for
ontrol of  mean  arterial  pressure  between  45  and  70  mmHg.
Upon  completion  of  the  surgical  procedure,  all  patients
eceived a  continuous  intravenous  infusion  of  2  g/kg/min
ropofol as  a  sedative  and  were  transferred  to  the  ICU,
here they  remained  sedated  for  a  1-h  period.  The  analge-
ia protocol  was  initiated  within  the  ﬁrst  24  h  with  a  single
ntravenous dose  of  1  g/kg  fentanyl  together  with  1  g  of
ypirone. The  same  dose  of  dypirone  was  repeated  every
 h.
After  tracheal  extubation,  patient  control  analgesia
venous PCA)  with  a  Vigon® PCA  pump  was  then  installed
ith the  following  parameters:  bolus  only  mode,  1  mg  bolus
nd a ﬁxed  7-min  lockout  interval.  During  this  period,  if
here was  signiﬁcant  pain  (VAS  >  7),  100  mg  of  tramadol  was
dministered intravenously.  Discharge  from  the  ICU  and  hos-
ital were  followed  by  local  protocols.
Hemodynamic  goals  during  anesthesia  were  maintenance
f central  venous  pressure  (CVP)  and  pulmonary  capillary
edge pressure  (PCP)  between  8  and  12  mmHg  with  adminis-
ration of  crystalloids  and  colloids  and  maintenance  of  mean
rterial pressure  (MAP)  between  60  and  80  mmHg.
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39.15 (25.77--54.88)  pg/mL  to  188.97  (84.31--247.96)  pg/mL
in control  group.  Blood  levels  of  IL-6  (Fig.  1)  and  TNF
(Fig. 2)  were  similar  between  groups.
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Hypotension  was  deﬁned  as  a  MAP  <  60  mmHg  (<45  mmHg
during CPB),  for  more  than  30  s.  Hypertension  was  deﬁned
as MAP  >  80  mmHg  (>70  mmHg  during  CPB),  for  more  than
30 s.
Management  of  hypotension  included  phenylephrine
0.1 mg  bolus  (when  anesthetic  agents  were  at  mini-
mum levels,  could  be  repeated  every  minute),  dopamine
(when anesthetic  agents  were  at  minimum  levels,  ﬁll-
ing pressures  were  high  and  when  CI  was  less  than
2.4 L/m2/min)  at  a  dose  of  5  g/kg/min  with  incre-
ments of  1  g/kg/min  until  the  desired  MAP  level  was
reached, norepinephrine  (when  the  CI  remained  below
2.4 L/m2/min  at  dopamine  doses  of  10  g/kg/min)  at  a  dose
of 0.1  g/kg/min,  with  increments  of  0.1  g/kg/min  until
the desired  MAP  level  was  reached.  Dopamine  use,  as  a  pri-
mary endpoint,  was  strictly  regulated  by  protocols,  such  as
documented low  CI  (less  than  2.4  L/m2/min),  high  CVP  or
PCWP.
Hypertension management  included  remifentanil  (bolus
0.5 g/kg  followed  by  an  infusion  dose  increase  of
0.1 g/kg/min  with  the  sequence  repeated  every  minute
till a  maximum  infusion  rate  dose  of  0.4  g/kg/min),  fol-
lowed by  sodium  nitroprusside  (0.5  g/kg/min  and  increased
by 0.5  g/kg/min  increments  until  the  maximum  dose  of
2 g/kg/min  was  reached).  Sevoﬂurane  was  used  when
the BIS  value  exceeded  65.  The  inspired  sevoﬂurane
concentration  was  increased  to  4%  and  fresh  gas  ﬂow  to
6 L/min  for  1  min  while  the  fresh  gas  ﬂow  was  returned
to 2  L/min  and  the  sevoﬂurane  concentration  was  reduced
to 2%.  If  the  BIS  did  not  return  to  pre-established  lev-
els, the  procedure  was  repeated  and  in  the  absence  of  a
response, a  dose  of  0.05  mg/kg  midazolam  was  adminis-
tered.
Clamping of  the  aorta  (maximum  duration  15  min  with  an
interval of  at  least  2  min)  was  performed  in  mild  hypother-
mia (34 ◦C).  Saline  solution  was  used  to  ﬁll  the  membrane
oxygenator (Vital® --  Nipro,  Brazil).
All  data  were  collected  by  trained  observers  who  were
not blinded  to  the  anesthetic  regimen  used.
Blood  tests  included  cardiac  troponin  I  (cTnI),  mea-
sured using  an  immunoassay  method  (CMIA  --  Architect®;
Abbott Laboratories,  Brazil,  --  the  normal  range  being
0--0.3 ng/mL),  B-type  natriuretic  peptide  (BNP),  measured
using an  immunoassay  method  (MEIA  --  AxSIM® system;
Abbott Laboratories,  Brazil  --  with  values  of  1400  pg/mL
for patients  with  NYHA  functional  class  I  and  3400  pg/mL
for those  with  functional  class  II  being  considered  normal
limits), interleukin  6  (IL-6)  and  tumor  necrosis  factor  
(TNF) measured  using  an  immunometric  assay  method  by
the IMMULITE® system  --  Siemens  Medical,  USA  --  the  normal
range being  <3.4  pg/mL  for  IL  6  and  <8.1  pg/mL  for  TNF.  All
blood tests  were  measured  at  baseline  while  BNP  and  cTnI
were measured  24  h  after  CPB  and  IL-6  and  TNF  10  min  after
anesthesia induction,  15  min,  6  h,  24  h  after  CPB  and  4  days
postoperatively.
On the  basis  of  previous  personal  data  we  anticipated
that the  amount  of  patients  needing  inotropic  support  with
dopamine would  have  been  10%  and  50%  in  sufentanil  and
control group,  respectively.  We  calculated  that  we  would
need a  sample  size  of  20  patients  per  group.  All  patients
were analyzed  according  to  the  intention-to-treat  princi-
ples, beginning  immediately  after  randomization.Figure  1  Blood  levels  of  interleukin  6  (IL-6).
tatistical analysis
ata  were  expressed  as  number  (percentage),
ean  ±  standard  deviation,  or  median  (interquartile
ange). Student’s  t-test,  Fisher’s  exact  test,  Pearson’s
hi-squared analysis  and  Mann--Whitney  nonparametric  test
ere used  when  appropriate  using  the  Statistical  Package
or the  Social  Sciences  software  (SPSS).  ANOVA  analysis
as used  for  repeated  measures  continuous  data,  such  as
iochemical markers.
esults
reoperative  data  were  well  balanced  between  sufentanil
nd control  group  (Table  1).  Patients  in  sufentanil  group
equired less  inotropic  support  with  dopamine  at  weaning
rom CPB  and  after  CPB  when  compared  to  control  group
9.5% vs  58%  p  =  0.001)  and  less  increases  in  remifentanil  use
62%  vs  100%  p  =  0.004)  as  showed  in  Table  2.
Cardiac troponin  I  was  detectable  in  all  patients
ostoperatively,  with  no  differences  between  groups:
.62 (0.80--5.59)  ng/mL  in  sufentanil  group  vs  1.68
0.73--3.53) ng/mL  in  control  group  (p  =  0.506).  Similarly,
NP was  detectable  in  all  patients  postoperatively,  with
o differences  between  groups  (p  =  0.667).  BNP  increased
rom 36.13  (21.70--73.79)  pg/mL  preoperatively  to  207.58
89.95--236.77) pg/mL  postoperatively  in  sufentanil  group  vsFigure  2  Blood  levels  of  tumor  necrosis  factor    (TNF).
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Table  1  Patients’  characteristics  and  surgical  times.  Data  are  expressed  as  number  and  percentages  or  as  mean  ±  standard
deviations.
Control  group
n =  19
Sufentanil  group
n =  21
Preoperative  data
Female gender  6  (32%)  7  (33%)
Age (years)  56  ±  7.2  58  ±  6.7
Body  mass  index  (kg/m)  26  ±  3.9  27  ±  2.5
ASA  II  19  (100%)  20  (95%)
ASA III  0  1  (4.8%)
NYHA I 7  (37%) 9 (43%)
NYHA II 12  (63%) 12 (57%)
Diabetes  Mellitus 6  (32%) 9 (43%)
Hypertension  15  (79%)  19  (90%)
Dyslipidemia  11  (58%)  16  (76%)
Smoking  5  (26%)  10  (48%)
Previous  myocardial  infarction  5  (26%)  6  (28%)
Intra-operative  data
Duration of  anesthesia  (min) 299  ± 57 292  ± 39.4
Duration of  surgery  (min) 235  ± 51.7 223  ± 35.5
Duration of  ischemia  (min) 52  ± 14.9 50  ± 15.0
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Hemodynamic  data  at  eight  different  time  points  (sup-
lemental material  I  online)  showed  no  differences  between
roups with  exception  of  minor  difference  after  CPB.
No  episodes  of  awareness  were  detected  in  this  study.
Table  3  shows  similar  consumption  of  analgesics  during
he ﬁrst  24  postoperative  hours  between  groups.
Time  on  mechanical  ventilation  was  300  (212--450)  vs  255
230--315) min  in  control  and  sufentanil  group  respectively
p = 0.4),  while  ICU  stay  was  2.7  +  0.89  vs  3.9  +  3.75  days
p = 0.2)  and  hospital  stay  was  8.9  +  6.98  vs  9.1  +  6.1  days,
espectively.
Table 4  shows  that  there  was  no  difference  in  postopera-
ive complications  except  for  the  need  for  blood  transfusion,
hich was  signiﬁcantly  higher  in  control  group  (4  patients,
1%) vs  sufentanil  group  (no  patient),  p  =  0.042.One patient  in  sufentanil  group  died  on  the  ﬁfth  postop-
rative day  because  of  a  computed  tomography  documented
troke that  occurred  on  the  third  postoperative  day.
t
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Table  2  Drugs  used  in  the  intra-operative  period.  Data  are  prese
Control  group
n =  19
Vasoactive  drugs
Dopamine 11  (58%)  
Phenylephrine  12  (63%)  
Sodium  nitroprusside  17  (89%)  
Anesthetic  agents
Sevoﬂurane  increases 0  
Remifentanil  bolus 19  (100%)  
Sevoﬂurane  (mL/h)  14  ±  2.4  
Remifentanil  (g/kg/min)  0.20  ±  0.05  23.0 69  ± 20.0
iscussion
he  main  result  of  this  study  is  that  patients  in  sufen-
anil group  had  more  hemodynamic  stability  as  suggested
y reduced  inotropic  support  and  few  adjustments  in  intra-
enous opioid  doses.
Our study  also  conﬁrms  that  neuraxial  techniques  pro-
uce effective  analgesia  in  patients  undergoing  cardiac
urgery as  demonstrated  by  a  reduced  consumption  of  intra-
enous remifentanil  in  patients  of  sufentanil  group.
On  the  contrary,  no  difference  was  noted  in  inﬂamma-
ory markers  (IL6  and  TNF)  and  in  cardiac  biomarkers
cTnI and  BNP).  Their  release  pattern  (cTnI,  IL6  and  TNF)
long time  was  the  same  as  observed  by  Meng  et  al.,10
onﬁrming  that  in  both  groups  inﬂammatory  response  due
o elevation  in  IL6  and  TNF  was  not  attenuated  and,
o cardiac  protection  due  to  reduction  in  cTnI  and  BNP
ccurred.
nted  as  number  (percentages)  or  mean  ±  standard  deviation.
Sufentanil group
n =  21
p
2  (9.5%)  0.001
9  (43%)  0.2
19  (90%)  0.9
3  (14%)  0.2
13  (62%)  0.004
14  ±  2.5  0.8
0.05  +  0.04  <0.001
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Table  3  Postoperative  data.  Data  are  expressed  as  number  (percentage),  median  ±  standard  deviation  or  median  (interquartile
range).
Variables  Control  group
n =  19
Sufentanil group
n =  21
p-Value
Tramadol  within  24  h,  no.  of  patients 13  (68%) 18  (86%)  0.3
Bolus  of  morphine,  number  of  boluses
per  patient
1.5  ±  1.26 1.2  ±  0.98 0.5
PCA morphine  consumption  24  h,  mg
per patient
8.0  ±  3.15  7.6  ±  3.25  0.8
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Our  study  could  only  be  compared  to  that  of  Bet-
tex and  colleagues4 who  performed  the  only  randomized
study administering  or  not  intrathecal  sufentanil  in
cardiac surgery,  although  they  added  morphine  to  sufen-
tanil intrathecal.  Their  postoperative  results  showed  that
combined sufentanil  and  morphine  allowed  a  shorter  post-
operative duration  of  intubation  and  adequate  analgesia
compared with  a  standard  intravenous  technique,  which  dif-
fers from  ours,  that  showed  no  difference  on  these  results.
In  a  non-randomized  study,  Swenson  and  colleagues2
found  that  the  combination  of  50  g  intrathecal  sufentanil
and 500  g  intrathecal  morphine  in  general  anesthesia  in
patients undergoing  CABG  promoted  greater  intraoperative
hemodynamic stability  and  reduced  the  intraoperative  con-
sumption of  intravenous  opioids.  In  our  study,  although  we
did not  use  morphine,  we  noted  that  the  use  of  intrathecal
sufentanil reduced  intraoperative  consumption  of  intra-
venous opioids.
Hansdottir and  colleagues11 performed  the  ﬁrst  study
about plasma  and  cerebral  spinal  ﬂuid  pharmacokinetics  of
sufentanil administered  intrathecal  in  thoracic  surgery.  In
their experience,  they  concluded  that  in  patients  under-
going thoracotomy,  administration  of  15  g  of  intrathecal
sufentanil in  combination  with  general  anesthesia  produced
a more  potent  analgesic  effect  with  a  faster  onset  of
action and  a  shorter  duration  compared  to  equipotent
doses of  morphine  or  meperidine.  This  was  attributed
to the  high  lipid  solubility  of  sufentanil  when  present
in the  cerebrospinal  ﬂuid  and  to  a  fast  transfer  to  the
plasma. However,  the  same  author  showed  that  the
cerebrospinal ﬂuid  (CSF)  and  plasma  concentrations  of
sufentanil did  not  reach  equilibrium  even  10  h  after  initial
V
s
t
Table  4  Postoperative  complications.  Data  are  expressed  as  num
Variables  Control
n  =  19
Reoperation  1  (5.3%)  
Re-intubation  0  
Major  Arrhythmias  2  (11%)  
Peri-operative  awareness  0  
Nausea  and/or  vomiting  5  (26%)  
Pruritus  0  
Death  0  
Need  for  blood  transfusion  4  (21%)  njection.  In  fact,  10  h  after  initial  injection,  the  CSF
oncentration was  still  10  times  higher  than  plasmatic  one.
his study  clariﬁed  that  the  principal  analgesic  effect  of
ufentanil administered  in  subarachnoid  space  is  via  local
ather than  systemic  absorption.
There  are  several  factors  that  may  determine  the  occur-
ence of  pain,  including  an  increase  in  time  required  to
xtubation and  the  occurrence  of  adverse  events  that
esult in  deteriorations  in  ventricular  function  during  post-
perative period  immediately  after  cardiac  surgery.12,13
ostoperative  pain  relief  following  cardiac  surgery  is  dif-
cult to  control.  In  our  study,  there  were  no  statistically
igniﬁcant differences  between  groups  with  respect  to  total
onsumption of  analgesics  over  a  24-h  period  after  extuba-
ion. These  results  demonstrated  that  the  proposed  scheme
f a  single  high  dose  of  intrathecal  sufentanil  was  not  suf-
cient to  promote  adequate  analgesia  over  the  initial  24-h
eriod following  removal  of  orotracheal  cannula.
Hansdottir  and  colleagues11 also  showed  that,  although
ufentanil is  more  lipophilic  and  is  eliminated  more  quickly
rom cerebrospinal  ﬂuid  than  other  opioids  such  as  mor-
hine, when  15  g doses  of  sufentanil  were  injected  into
he subarachnoid  space,  the  concentration  of  opioid  in  cere-
rospinal ﬂuid  remained  at  residual  concentrations  15  ±  5
imes higher  than  in  plasma  for  up  to  10  h  (600  min)  follow-
ng the  injection.  Fournier  and  colleagues,14 in  a  study  where
atients underwent  surgery  for  total  hip  replacement,  con-
luded that  a  single  7.5  g  dose  of  intrathecal  sufentanil
as sufﬁcient  to  reduce  pain  intensity  and  maintain  the
AS value  below  3  for  a  period  of  224  ±  100  min.  In  our
tudy, doses  of  intrathecal  sufentanil  administered  were  up
o seven  times  higher  than  those  proposed  by  Hansdottir  and
ber  (percentages).
Sufentanil
n  =  21
p-Value
0  0.5
1  (4.8%)  0.9
0  0.2
0  --
1  (4.8%)  0.085
0  --
1  (4.8%)  0.9
0  0.042
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18  
4  times  higher  than  those  proposed  by  Fournier  but  still  had
ffect only  in  perioperative  period  and  not  in  postoperative
ain control.
Increased need  for  packed  cells  in  control  group  was  an
nexpected ﬁnding  and  authors  cannot  ﬁnd  a  physiopatho-
ogical hypothesis  to  justify  it  (it  is  probably  an  effect  of  the
mall sample  size).
In our  institution,  we  considered  inhalation  induction
or cardiac  surgery  because  it  is  easy  to  perform  even  in
dult patients  and  it  has  better  hemodynamic  stability  com-
ared to  some  intravenous  agents,  as  described  by  other
uthors.15,16
The  spinal  dose  of  1  g/kg,  limited  to  100  g,  is  used  in
ur institution  because  we  agree  with  authors  that  conclude
he main  action  of  sufentanil  is  in  the  spinal  cord,11 and  so,
oses related  to  weight  or  height  would  guarantee  greater
SF dispersion  in  patients  with  more  weight  or  height,  result-
ng in  higher  levels  of  analgesia  and  hence  better  control  of
timuli from  the  high  thoracic  incision,  different  from  Swen-
on and  Bettex,2,4 that  describe  a  single  intrathecal  dose  of
0 g  of  sufentanil  for  cardiac  surgery.
imitations  of  the  study
he  study  was  not  blinded  to  use  of  intrathecal  sufentanil.
onetheless, all  protocols  included  in  the  study  were  fol-
owed rigorously.
onclusion
he  main  result  of  this  study  is  that  patients  receiving
ntrathecal sufentanil  have  more  hemodynamic  stability
hen compared  to  those  receiving  a  standard  treatment,  as
uggested by  reduced  inotropic  support  (dopamine  support
t weaning  from  CPB  and  during  the  perioperative  period
o maintain  hemodynamic  values)  and  few  adjustments  in
ntravenous opioid  doses.
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